A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

Vaccine

Volumn 27, Issue 1, 2009, Pages 107-115

  Navabi, H ^a   Jasani, B ^b   Reece, A ^a   Clayton, A ^b   Tabi, Z ^b   Donninger, C ^c   Mason, M ^b   Adams, M ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Bioclones (Ltd)   (South Africa)

Author keywords

Dendritic cell; Immunotherapy; Maturation; Poly (I:C12U)

Indexed keywords

ADJUVANT; AMPLIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASKI CELL; CELL MATURATION; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; TH1 CELL; TUMOR CELL DESTRUCTION; VOLUNTEER;

ANTIVIRAL AGENTS; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLY I-C; POLY U; TH1 CELLS; TISSUE DONORS;

EID: 56949108633     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.024     Document Type: Article

References (41)

1. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 4 (Apr 2005) 296-306
2. Sparwasser T., Koch E.S., and Vabulas R.M. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28 6 (1998) 2045-2054
3. Zitvogel L., Mayordomo J.I., and Tjandrawan T. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183 1 (1996) 87-97 [see comment]
4. Brunda M.J., Luistro L., and Warrier R.R. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178 4 (1993) 1223-1230
5. + CTLs from naive precursors. J Immunol 153 3 (1994) 996-1003
6. (+) T cells resulting in a failure to lyse tumor cells. Blood 93 5 (1999) 1634-1642
7. Bender A., Sapp M., Schuler G., Steinman R.M., and Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 196 2 (1996) 121-135
8. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 171 5 (2003) 2251-2261
9. Verdijk R.M., Mutis T., and Esendam B. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. Jo Immunol 163 1 (1999) 57-61
10. Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. 1976 September; 599-602.
11. Strayer DR, Carter WA, Brodsky I. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. 1994; 88-95.
12. Thompson K.A., Strayer D.R., and Salvato P.D. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 15 7 (1996) 580-587
13. 12U] Clinical investigators brochure Bioclones (PTY) Ltd. South Africa; 1998.
14. Adams M., Navabi H., and Jasani B. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen R). Vaccine 21 (2003) 787-790
15. Romani N., Gruner S., and Brang D. Proliferating dendritic cell progenitors in human blood. J Exp Med 180 1 (1994) 83-93
16. Jonuleit H., Giesecke-Tuettenberg A., and Tuting T. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93 2 (2001) 243-251
17. Gallucci S., Lolkema M., and Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5 11 (1999) 1249-1255
18. Doyle A, Griffiths J, Newell D, (eds.), Estabishment of human B lymphoblastoid cell lines from peripheral blood mononuclear cells. In: Cell and tissue culture laboratory procedures. Porton Down . Wiley, Salisbury, UK, 1994, 21-26.
19. Santin A.D., Bellone S., Palmieri M., Bossini B., and Pecorelli S. Restoration of tumor specific human leukocte antigens class I - restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocy in patients with advanced ovarian cancer. Int J Gynecol Cancer 14 (2004) 64-75
20. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. [see comment]. 1998 March, 328-332.
21. Ressing M.E., van Driel W.J., and Brandt R.M. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23 2 (2000) 255-266
22. Kimura J., Takada H., Nomura A., and Ohno T. Th1 and Th2 cytokine production is suppressed at the level of transcriptional regulation in Kawasaki disease. Clini Exp Immunol 137 (2004) 444-449
23. Figdor C.G., de Vries I.J., Lesterhuis W.J., and Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 10 5 (2004) 475-480
24. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 6 6 (2006) 476-483
25. Gattinoni L., Powell Jr. D.J., Rosenberg S.A., and Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6 5 (2006) 383-393
26. + T cells exceeds that of an aggressively growing mouse tumor. Cancer Res 66 2 (2006) 1132-1138
27. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211 (2006) 214-224
28. + T cells. Immunol Rev 211 (2006) 81-92
29. Curtsinger J.M., Johnson C.M., and Mescher M.F. CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol 171 10 (2003) 5165-5171
30. Adams M., Navabi H., and Croston D. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23 17-18 (2005) 2374-2378
31. Schulz O., Edwards A., and Schito M. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13 (2000) 453-462
32. Mailliard R., Wankowicz-Kalinska A., Hilkens C., Kapsenberg M., and Kalinski P. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64 (2004) 5934-5937
33. Hilkens C., Kalinski P., de Boer M., and Kapsenberg M. Human dendritic cells require exogenous iterleukin-12 inducing factor to direct the developmentof naive T-Helper cells toward the Th1 phenotype. Blood 90 (1997) 1920-1926
34. Snijders A., Kalinski P., Hilkens C., and Kapsenberg M. High-level IL-12 production by human dendritic cells reqires two signals. Int Immunol 10 11 (1998) 1593-1598
35. + cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Therapy 13 (2006) 1027-1036
36. McBride S., Hoebe K., Georgel P., and Janssen E. Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol 177 9 (2006) 6122-6128
37. Ijichi K., Mitamura K., Ida S., Machida H., and Shimada K. In Vivo Antiviral Effects of Mismatched Double-Stranded RNA on Duck Hepatitis B Virus. J Med Virol 43 (1994) 161-165
38. Welters M.J., Bijker M.S., and Van den Eeden S. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 25 (2007) 1379-1389
39. 12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 178 (2007) 5200-5208
40. Chaput N., Schartz N.E., and Andre F. Exosomes as a potent cell-free peptide-based vaccine. II. exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumour rejection. J Immunol 172 (2004) 2137-2146
41. Adams M. Vaccination with autologous ovarian cancer ascites derived exosomes in combination with systemic adjuvant treatment with poly I:polyC12U (Ampligen): a phase 1/2 clinical study in patients with advanced ovarian cancer. 2007.